Short Interest & Thesis

Short Interest & Thesis — Molina Healthcare (MOH)

Bottom line. Official reported short interest is not decision-useful here: the short-interest data feed returned zero reported-position rows, zero short-sale-volume rows, and zero borrow rows for MOH, so there is no staged days-to-cover, % of float, or borrow-cost figure to anchor a "crowding" call. What is material — and well documented in the primary record — is a credible, fundamentally grounded bear case: a ~260 bp consolidated medical-cost-ratio (MCR) blow-out in 2025, a self-inflicted guidance reset from an original \$24.50 EPS to \$14 and then a 2026 floor of "at least \$5," a Medicaid/Marketplace rate-adequacy gap that management concedes runs into the hundreds of basis points, looming OBBBA Medicaid cuts, and a securities class action and derivative suit filed in late 2025 over the very guidance that collapsed. The strongest evidence is the company's own filings and calls; the weakest link is the missing market-structure data — so positioning risk here should be read off liquidity and the thesis, not off an unavailable short-interest number.

Evidence availability — what we have and what we do not

Source: short-interest data feed (reported short interest / short-sale volume / borrow), as staged — all channels returned empty; narrative channel from MOH FY2025 Form 10-K and FY2025–Q1 FY2026 earnings-call transcripts.

Because the reported-position channel is empty, this tab is a thesis-risk and liquidity assessment, not a short-positioning readout. A reader wanting an official short-interest number should treat it as a known gap and pull it from the exchange/FINRA feed directly.

Liquidity and float backdrop — why days-to-cover cannot be computed

Days-to-cover and "% of float" both require a reported short-interest figure that does not exist in this run. What can be stated is the liquidity into which any short position — large or small — would have to cover.

Source: share count from FY2025 Form 10-K Consolidated Statements [1]; volume from staged daily price data, as reported.

MOH is a liquid ~\$11–12B-cap NYSE name with roughly 1.5M shares trading per day and only ~1.4% insider ownership, so essentially the entire ~52.9M share count is float. The share count has fallen every year — from 66.6M (FY2018) to 52.9M (FY2025) — driven by buybacks, so a "dilution" leg to any short thesis does not hold. The constraint on a short here is thesis durability, not borrow scarcity or cover mechanics, neither of which the data supports commenting on.

The fundamental short case — sourced to MOH's own record

There is no public short-seller report or activist campaign in the corpus. The bear case instead reads straight off the filings: a 2025 medical-cost shock that broke guidance and drew securities litigation. The ledger below separates each allegation from its supporting evidence, the company's response, and what remains unresolved.

Sources: consolidated MCR [2]; Medicare and Marketplace MCR and membership [3]; guidance reset [4] [5]; rate-adequacy gap [6]; OBBBA [7]; securities litigation [8].

The single most important point for a PM: the bear case is endorsed by the company's own disclosures. The consolidated MCR climbed to 91.7% in 2025 from 89.1% in 2024, explicitly above Molina's long-term target range, on utilization "higher than we expected" [9]. Marketplace was the epicenter — MCR jumping to 90.6% from 75.4% while the company simultaneously grew the book to 655,000 members [10]. Management itself quantified the reset: an original \$24.50 EPS plan revised to \$14, "half of this revision emerges from the unprecedented utilization trend in Marketplace" [11], and conceded the Medicaid book "needs 300 to 500 basis points to break even, just to break even" [12]. That is the rare case where the short narrative and the issuer narrative converge — the disagreement is over durability, not facts.

Medical cost ratio — the trend a short leans on

Sources: FY2025 levels (2024–2025) [13]; earlier levels (2020–2022) [14].

For four years the consolidated MCR sat in a tight 88.0%–89.1% band; the 2025 jump to 91.7% is a 2.6-point step-change that flows almost entirely to the bottom line in a thin-margin managed-care model — the reason net income fell to \$472M in 2025 from \$1,179M in 2024 even as revenue grew to \$45.4B. The chart is the short thesis in one line: a stable cost structure that broke.

The earnings reset — what management itself guided

Sources: $24.50 to $14 revision [15]; FY2026 floor of at least $5 [16].

The FY2026 floor of "at least \$5" is explicitly "burdened by \$1.50 of new contract performance of the Landmark Florida CMS contract and a dollar due to the underperformance" [17] — i.e. management frames it as a sandbagged trough rather than a steady-state. The early read supports the recovery framing: Q1 2026 delivered \$2.35 adjusted EPS on a 91.1% MCR with cost trend "modestly favorable to our expectations," and the year was reaffirmed [18]. For a short, that is the key tension: the thesis is true on the 2025 facts but is fighting a company guiding to stabilization in 2026.

Management's response — buying back stock into the drawdown

A material rebuttal to the bear case is that Molina kept repurchasing shares as the stock fell, rather than retrenching.

Source: FY2025 Form 10-K, Note 13 Stockholders' Equity [19].

Molina bought \$500M of stock in Q1 2025 at an average \$297.83, then another \$500M in Q3 at \$175.50 — repurchasing more shares at a ~41% lower price as the cost-trend news broke [20]. In April 2025 the board authorized a fresh \$1B program through year-end 2026, of which \$500M remained available as of February 10, 2026 [21]. That standing authorization is a structural counterweight to short pressure: a steady buyback bid in a liquid, near-fully-floated name limits how cleanly a short can press the tape.

Market setup — what to watch

Without reported short interest, the positioning read is qualitative:

• Catalyst asymmetry is two-sided. The 2025 cost shock and the still-pending securities case [22] keep downside live if 2026 MCR re-accelerates; but the stock already round-tripped a severe drawdown (2025 buybacks span \$297.83 down to \$175.50) and recovered in 2026, so a continued cost-trend improvement is a squeeze-type upside catalyst against any unhedged short.
• Borrow is a blind spot. With no staged borrow data, there is no basis to claim hard-to-borrow status or fee pressure either way — treat borrow as unknown, not benign.
• Regulatory tail (OBBBA). Medicaid work requirements and more frequent redeterminations are a slower-burn structural negative that a fundamental short can hold past the 2026 print [23].

Peer context

No peer short-interest rows were staged, so a true cross-name crowding comparison is not possible. Qualitatively, the 2024–2025 medical-cost-trend shock is an industry-wide managed-care phenomenon (Centene, Cigna, and Elevance disclose related Marketplace/Medicaid pressures), so MOH's bear case is a sector theme expressed acutely in a Marketplace-heavy mix — not an idiosyncratic fraud or accounting allegation. Absent comparable short-interest figures, any statement that MOH is more or less shorted than peers would be unsupported and is not made.

Evidence quality

Source: short-interest data feed (empty across reported / flow / borrow / peer channels), as staged; narrative channels from MOH FY2025 Form 10-K and FY2025–Q1 FY2026 transcripts [24].

Net: short-interest positioning is not decision-useful in this run for lack of data, but the thesis risk is real, fundamentally grounded, and partly litigated — a PM should size and time around the 2026 MCR trajectory and the securities case, not around an unavailable short-interest print.